Our lab studies gene mutations that drive the cancers known as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In particular, we are focused on mutations in the spliceosome complex, including SF3B1 and SRSF2. We use engineered human cell models, primary patient leukemia samples, mouse xenografts, and correlative clinical data to characterize how these mutations disrupt RNA splicing, affect cancer phenotypes, and create therapeutic vulnerabilities. The ultimate goal for our work is to improve the lives of patients with MDS and AML.